Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tetwtCEA DNA Vaccine in Colorectal Cancer
NCT01064375Phase 2Completed
- Sponsor
- Maria Liljefors AB
- Start
- Dec 2009
- Primary completion
- Mar 2012
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label trial of tetwtCEA DNA in colorectal cancer (CRC) (3 arms), sponsored by Maria Liljefors AB. Primary endpoints: Safety of tetwtCEA DNA with electroporation at 72 weeks and Immunogenicity of tetwtCEA DNA with electroporation at 72 weeks. Started Dec 2009; status: completed.
02
Drugs
tetwtCEA DNA
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01064375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01064375.